Moderna se dispara casi un 90% en Bolsa tras el éxito de un ensayo clínico contra el cáncer de piel
La farmacéutica, junto a Merck, que sube cerca del 8%, han anunciado la obtención de resultados preliminares positivos en el ensayo clínico de una vacuna para el melanoma. Leer
Moderna and Merck shareed sharp gains on the New York Stock Exchange after delivering promising preliminary results from a clinical trial of a melanoma vaccine. The pharmaceutical companies announced positive early findings from a phase 3 trial of a personalized neoantigen vaccine based on mRNA, marking a key moment in cancer research.
Moderna's shares surged nearly 90% to $118 per share, up from $62.96 at the close of the previous trading session. Merck's stock also rose by nearly 8% to $145 per share, surpassing its previous close of $135.17. The companies collaborated on this innovative treatment, combining Moderna's mRNA therapy with Merck's already approved drug Keytruda.
The trial demonstrated statistically significant and clinically relevant improvements in recurrence-free survival and progression-free survival in patients with melanoma, the most serious form of skin cancer. Dr. Stéphane Bancel, Moderna's CEO, emphasized that the trial's results bring the concept of creating patient-specific mRNA cancer treatments closer to reality.
Merck's Dr. Dean Y. Li added that administering the treatment at an early stage, after surgery, could significantly boost the chances of cure for a larger number of patients.
Written by urgent.news from Expansion ES's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
